Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 17;129(2):249–265. doi: 10.1038/s41416-023-02282-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a Relative cell viability in BCPAP cells upon single (PLX4032 and diclofenac) and combined treatment with the two drugs at different doses for 72 h. Data are reported as mean ± SEM vs control cells (i.e., BCPAP treated with the vehicles—indicated as dotted line—are set to 100% of viability) of at least four independent experiments. **P value ≤0.01 and ***P value ≤0.001 vs control cells or BCPAP treated with the maximum dose of PLX4032 (5 µM). ^###P value ≤0.001 vs BCPAP treated with the same doses of PLX4032 alone. ^§§P value ≤ 0.01 vs BCPAP treated with the same doses of diclofenac alone. b Heatmap showing—in 2D (left panel) and 3D (right panel)—the HSA synergy scores (i.e., positive values in red denote synergy), analysed by SynergyFinder tool, for the combination of PLX4032 and diclofenac in BCPAP. c Relative cell viability in 8505c cells upon single (PLX4032 and diclofenac) and combined treatment with the two drugs at different doses for 72 h. Data are reported as mean ± SEM vs control cells (i.e., 8505c treated with the vehicles—indicated as dotted line—are set to 100% of viability) of at least four independent experiments. ***P value ≤0.001 vs control cells or 8505c treated with the maximum dose of PLX4032 (10 µM). ^#P value ≤0.05, ^##P value ≤0.01 and ^###P value ≤0.001 vs 8505c treated with the same doses of PLX4032 alone. ^§§P value ≤0.01 and ^§§§P value ≤0.01 vs 8505c treated with the same doses of diclofenac alone. d Heatmap showing—in 2D (left panel) and 3D (right panel)—the HSA synergy scores (i.e., positive values in red denote synergy), analysed by SynergyFinder tool, for the combination of PLX4032 and diclofenac in 8505c. e Relative cell viability in 8505c cells upon single (dabrafenib or diclofenac) and combined treatment with the two drugs at different doses for 72 h. Data are reported as mean ± SEM vs control cells (i.e., 8505c treated with the vehicles—indicated as dotted line—are set to 100% of viability) of at least three independent experiments. *P value ≤0.05 and ***P value ≤0.001 vs control cells or 8505c treated with the maximum dose of DBR (0.5 µM). ^##P value ≤0.01 and ^###P value ≤0.001 vs 8505c treated with the same doses of dabrafenib alone. ^§P value ≤0.05 and ^§§§P value ≤0.01 vs 8505c treated with the same doses of diclofenac alone. f Heatmap showing—in 2D (left panel) and 3D (right panel)—the HSA synergy scores (i.e., positive values in red denote synergy), analysed by SynergyFinder tool, for the combination of dabrafenib and diclofenac in 8505c.